The new ACS guideline also recommends people should continue regular colorectal cancer screening through the age of 75.

Shares of diagnostic company Exact Sciences Corp, which makes Cologuard devices that helps detect colorectal cancer, rose by more than 10% after the guideline was revealed.

The move comes as a study showed that there has been a marked increase in colorectal cancer incidence, particularly rectal cancer, among younger individuals.

“While we commend the ACS for its forward thinking … we do not believe this will necessarily be a big driver of Cologuard volume upside for Exact Sciences in the near term,” William Blair analyst Brian Weinstein said.

Weinstein noted that Cologuard is currently approved for colon cancer screening for people between the ages of 50 and 84, adding that the company would need to run a separate trial for lower age groups.

Exact Sciences Chief Executive Officer Kevin Conroy said Cologuard is a cheaper way to screen younger people.

“First, we need to do clinical work to establish the safety and efficacy of Cologuard in that population,” Conroy said.

Colorectal cancer is the third-leading cause of cancer-related deaths in men and women in the United States and is expected to cause about 50,630 deaths during 2018.

American Cancer Society Cancer Action Network, a non-partisan advocacy affiliate of ACS, said it intends to officially recommend reconsideration of a guideline from US Preventive Services Task Force (USPSTF).

Currently, USPSTF, a government-backed independent panel that assesses the evidence for medical procedures, recommends screening from the age of 50.

USPSTF’s 2016 recommendation was based on a review of the available evidence on benefits and harms of colorectal cancer screening, USPSTF Chairwoman Sue Curry said.

“At the time of the Task Force’s review, there was limited data on screening adults younger than age 50.”